NYSE · Healthcare · Medical Instruments & Supplies · USA
Becton Dickinson & Co is a large cap company (market value between $10 billion and $200 billion) in the Medical Instruments & Supplies industry.
Becton Dickinson is a global medical technology company manufacturing and distributing a broad range of healthcare products for hospitals, clinics, laboratories and pharmaceutical companies. The company's three divisions provide solutions spanning medication administration, infection control, surgical interventions, drug delivery systems and disease detection across clinical and research settings.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Becton Dickinson & Co stock.
Fairly valued: intrinsic value $187.66 per share, market price $190.74, margin of safety -1.6% (as of 2026-10-19).
Discounting its cash flows at 7.0% (average of 3 methods) values the shares at $187.66; the price of $190.74 is 2% above that value, and 83% of that value comes from beyond year five.
Leak Score: 43/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 50 Medical Instruments & Supplies stocks
BDX is fairly valued (as of the 2026-10-19 close). Discounting its cash flows at 7.0% (average of 3 methods) values the shares at $187.66; the price of $190.74 is 2% above that value, and 83% of that value comes from beyond year five.
$187.66 per share (as of the 2026-10-19 close), against a market price of $190.74. That is a margin of safety of -1.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for roughly the growth the company has already delivered. No miracle needed, no discount either. Yearly sales growth the price needs: 4.7%. Yearly sales growth it has sustained: 4.2%.
43 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.